Baxter said fourth-quarter sales from continuing operations for Q4 were $3.89 billion, up 4% on a reported basis and 3% on a constant currency basis. Continuing operations exclude the BioPharma Solutions business.

1. 01

   Baxter said fourth-quarter sales from continuing operations for Q4 were $3.89 billion, up 4% on a reported basis and 3% on a constant currency basis. Continuing operations exclude the BioPharma Solutions business.

2. 02

   The company said fourth-quarter U.S. GAAP diluted earnings per share from continuing operations for Q4 were $0.14, and adjusted diluted earnings per share were $0.88. It said the results included total special items of $189 million.

3. 03

   The company said full-year operating cash flow from continuing operations was $1.70 billion and free cash flow was $1.01 billion. Free cash flow is operating cash flow from continuing operations less capital expenditures of $692 million.

4. 04

   The company expects full-year 2024 sales growth of about 2% on both a reported and constant currency basis, and adjusted earnings before special items of $2.85 to $2.95 per diluted share.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.